ALFA Finder| Revenue growth | 16% YoY Standalone; ₹304.17 Cr reported. |
|---|---|
| Margins | Standalone EBITDA margin expanded from 3% to 8% YoY. |
| Demand visibility | Strong outlook for cephalosporin antibiotics across emerging markets. |
| Management confidence | High, citing inflection point and integrated platform benefits. |
Growth
Standalone Revenue grew 16% YoY to ₹304 Cr. Standalone EBITDA surged 178% YoY to ₹25 Cr; PAT turned positive at ₹12 Cr vs loss of ₹3 Cr YoY.
Outlook
Focusing on KSM, FDF, and innovative products. Integration complete with multiple growth engines moving from concept to execution.
Risks
Other income declined 38% standalone. Financial results for prior periods were revised to reflect the amalgamation effects.
Last quarter's promises, checked
Delivered
- Guided FY27 base business growth 10-15% → delivered 16% YoY (= BEAT)
- Guided FY27 EBITDA margin ~12% for base business → delivered 8% Standalone (= MISS)
- Guided Dhanuka-Orchid merger completion shortly → delivered Effective July 10, 2026 (= BEAT)
Partly delivered
- Guided 7ACA commissioning Q1CY27 → delivered Project remains on track (= PARTIAL)
Missed
- Guided Enmetazobactam deal every quarter → delivered No new deal announced (= MISS)
Investor Presentation filed with NSE, NSE: ORCHPHARMA. Summary written with AI assistance from the document.
Orchid Pharma Ltd: key numbers
- Share price
- ₹877.00
- Market cap
- ₹5,252 Cr
- Revenue (annual)
- ₹811.3 Cr
- Net profit (annual)
- ₹20.55 Cr
- P/E (TTM)
- 605.9×Sector 43.8×
- Promoter holding
- 74.45%+4.61% QoQ
- FII holding
- 0.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Orchid Pharma Ltd
All →Orchid Pharma Board Meeting Date
Orchid Pharma Ltd intimated that its board will meet on November 14, 2026 to consider Q2 and half-year unaudited results. The trading window stays closed until 48 hours after results declaration.
Orchid Pharma Partnership
Orchid Pharma entered a licensing and supply agreement with Laboratorio Libra for Exblifep across nine Latin American markets. The partnership is expected to represent a potential opportunity of about USD 80 million over 10 years.
Orchid Pharma Fund Raise of ₹600 Cr
Orchid Pharma's board approved an enabling resolution to raise funds of up to ₹600 Crore through equity or debt securities via various permissible modes.
- Value
- ₹600.0 Cr
Orchid Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Orchid Pharma Board Meeting Date
Orchid Pharma has scheduled a board meeting for October 20, 2026, to consider options for raising funds. The company will explore various suitable funding avenues.
Orchid Pharma Other Announcement
Orchid Pharma Ltd has filed its quarterly Shareholding Pattern, providing a routine update on promoter and public shareholding as mandated by SEBI regulations.